

## REPORT

Tel No: 919823027643

PID: 11136697

Age:58.01 Years Sex:FEMALE

<u>Complete Blood Count</u>	<u>Result</u>	<u>Biological Reference Interval</u>
(EDTA Whole Blood)		
<b>Hemoglobin (Hb), EDTA whole blood</b>	<b>13.60</b>	12.3 - 15.3 g/dL
Method: Photometry		
<b>Total Leucocytes (WBC) count</b>	<b>6,400</b>	4000-10000/μL
Method : Coulter Principle / Microscopy		
<b>Platelet count</b>	<b>389,000</b>	150000 - 450000 /μL
Method : Coulter Principle / Microscopy		
<b>Red blood cell (RBC) count</b>	<b>5.12</b>	4.10 - 5.10 x 10 <sup>6</sup> /μL
Method: Coulter Principle		
<b>PCV (Packed Cell Volume)</b>	<b>40.50</b>	35.9 - 44.6 %
Method: Calculated		
<b>MCV (Mean Corpuscular Volume)</b>	<b>79.00</b>	80.0 - 96.0 fL
Method: Derived from RBC histogram		
<b>MCH (Mean Corpuscular Hb)</b>	<b>26.60</b>	27.5 - 33.2 pgms
Method: Calculated		
<b>MCHC (Mean Corpuscular Hb Conc.)</b>	<b>33.70</b>	33.4 - 35.5 g/dL
Method: Calculated		
<b>RDW (RBC distribution width)</b>	<b>13.60</b>	11.6 - 14.6 %
Method: Derived from RBC Histogram		
<b>WBC Differential Count</b>		
Method: VCSn / Microscopy / Calculated		
<b>Neutrophils</b>	<b>54</b>	40 - 80 %
<b>Absolute Neutrophils</b>	<b>3,456</b>	2000 - 7000 /μL
<b>Eosinophils</b>	<b>06</b>	1 - 6 %
<b>Absolute Eosinophils</b>	<b>384</b>	20 - 500 /μL
<b>Basophils</b>	<b>00</b>	0 - 2 %
<b>Absolute Basophils</b>	<b>0</b>	0 - 100 /μL
<b>Lymphocytes</b>	<b>34</b>	20 - 40 %
<b>Absolute Lymphocytes</b>	<b>2,176</b>	1000 - 3000 /μL
<b>Monocytes</b>	<b>06</b>	2 - 10 %
<b>Absolute Monocytes</b>	<b>384</b>	200 - 1000 /μL
-	<-->	

## REPORT

PRAJAKTA G KALE

Reference:Dr.--

SID: 119155495

Collection Date:

04-03-2020 08:54 AM

Sample Date:

04-03-2020 08:54 am

Report Date:

04-03-2020 02:15 PM

Tel No: 919823027643

PID: 11136697

Age:58.01 Years Sex:FEMALE

### Complete Blood Count Findings

R.B.C. : Normocytic, Normochromic

W.B.C. : No abnormality detected

Platelets : Adequate

Remark : --

.  
.   
.   
.   
.



Dr.(Mrs.) Manisha S. Patwardhan  
MD, DPB Reg.No.: 69229

## REPORT

Tel No: 919823027643

PID: 11136697


Age:58.01 Years Sex:FEMALE

Test Description	Observed Value	Biological Reference Interval
<b><u>Lipid Profile Maxi :</u></b>		
Serum Appearance	Clear	
Cholesterol (Total), serum by Enzymatic method	182	Desirable : < 200 mg/dL Borderline high : 200 - 239 mg/dL High : >= 240 mg/dL
Triglycerides, serum by Enzymatic method	82	Normal : < 150 mg/dL Borderline high : 150-199 mg/dL High : 200-499 mg/dL Very high : >= 500 mg/dL
HDL Cholesterol, serum by Enzymatic method	48	Men : > 40 mg/dL Women : > 50 mg/dL
VLDL Cholesterol, serum by calculation	16	< 30 mg/dL
LDL Cholesterol, serum by calculation	118	Optimal : <100 mg/dL Near optimal/above optimal : 100-129 mg/dL Borderline high : 130-159 mg/dL High : 160-189 mg/dL Very high : >= 190 mg/dL
Cholesterol(Total)/HDL Cholesterol Ratio	3.79	Males : Acceptable ratio <= 5.00 Females : Acceptable ratio <= 4.50
LDL Cholesterol/HDL Cholesterol Ratio	2.45	Males : Acceptable ratio <= 3.60 Females : Acceptable ratio <= 3.20
Apolipoprotein A1, serum by Nephelometry	141	125 to 215 mg/dL
Apolipoprotein B, serum by Nephelometry	80	Female : 55 to 125 mg/dL

**Reference : ATP III, NCEP Guidelines and National Lipid Association (NLA) 2014 Recommendations**

As per most international and national guidelines including Lipid Association of India 2016 :

1. Lipoprotein and lipid levels should be considered in conjunction with other atherosclerotic cardiovascular disease (ASCVD) risk determinants to assess treatment goals and strategies.
2. Non-fasting lipid levels can be used in screening and in general risk estimation.



**Dr.(Mrs.) Manisha S. Patwardhan**  
MD, DPB Reg.No.: 69229

**REPORT**

Tel No: 919823027643


PID: 11136697

Age:58.01 Years Sex:FEMALE

**Test Description****Observed****Biological Reference Interval****Liver Function Test :**

Bilirubin-Total, serum by Diazo method	<b>0.35</b>	0.10 - 1.20 mg/dL Neonates : Upto 15.0 mg/dL
Bilirubin-Conjugated, serum by Diazo method	<b>0.15</b>	Upto 0.3 mg/dL
Bilirubin-Unconjugated, serum by calculation	<b>0.20</b>	0.1 to 1.0 mg/dL
SGOT (AST), serum by Enzymatic method	<b>24</b>	15 - 37 U/Lt
SGPT (ALT), serum by Enzymatic Method	<b>28</b>	14 to 59 U/Lt
Alkaline Phosphatase,serum by pNPP-kinetic	<b>92</b>	Adult Female : 46 - 116 U/Lt
Protein (total), serum by Biuret method	<b>6.62</b>	6.4 to 8.2 g/dL
Albumin, serum by Bromocresol purple method	<b>3.89</b>	3.4 to 5.0 g/dL
Globulin, serum by calculation	<b>2.73</b>	2.3 - 3.5 g/dL

--XX--


**Dr.(Mrs.) Manisha S. Patwardhan**  
 MD, DPB Reg.No.: 69229

**REPORT**

Tel No: 919823027643

PID: 11136697

Age:58.01 Years Sex:FEMALE

Test Description	Observed Value	Biological Reference Interval
<u>TEST NAME</u>		

Glycated Hemoglobin (HbA1C), by HPLC	<b><u>6.20</u></b>	4.0 to 5.6 %
--------------------------------------	--------------------	--------------

**Interpretation :**

HbA1C level reflects the mean glucose concentration over previous 8-12 weeks and provides better indication of long term glycemic control.

**For diagnosis of Diabetes Mellitus (>= 18 yrs of age) :**

5.7 % - 6.4 % : Increased risk for developing diabetes.

>= 6.5 % : Diabetes

**Therapeutic goals for glycemic control :**

Adults : < 7%

Toddlers and Preschoolers : < 8.5% (but > 7.5 %)

School age (6-12 yrs) : < 8%

Adolescents and young adults (13 - 19 yrs) : < 7.5 %


Levels of HbA1C may be low as result of shortened RBC life span in case of hemolytic anemia.

Increased HbA1C values may be found in patients with polycythemia or post splenectomy patients.

Patients with Homozygous forms of rare variant Hb(CC,SS,EE,SC) HbA1c can not be quantitated as there is no HbA. In such circumstances glycemic control can be monitored using plasma glucose levels or serum Fructosamine.

The A1c target should be individualized based on numerous factors, such as age, life expectancy, comorbid conditions, duration of diabetes, risk of hypoglycemia or adverse consequences from hypoglycemia, patient motivation and adherence.

Ref : ADA (Standards of Medical Care in Diabetes - 2017)



**Dr.(Mrs.) Manisha S. Patwardhan**  
MD, DPB Reg.No.: 69229

## REPORT

PRAJAKTA G KALE

Reference:Dr.--

SID: 119155495

Collection Date:

04-03-2020 08:54 AM

Sample Date:

04-03-2020 08:54 am

Report Date:

04-03-2020 02:15 PM

Tel No: 919823027643

PID: 11136697

Age:58.01 Years Sex:FEMALE

### Test Description

### Observed Value

### Biological Reference Interval

#### Haematology :

Erythrocyte Sedimentation Rate, EDTA Whole Blood

11

Female under 50 Yrs : Upto 20mm/hr.

Female 50 - 85 Yrs : Upto 30mm/hr.

Female > 85 yrs : Upto 42mm/hr.

Results corrected to 18 deg. celsius

*Technique : Automated Westergren Method .*

*1. ESR is markedly elevated in monodonal gammopathy such as multiple myeloma, in severe polyclonal hyperglobulinemia due to inflammatory disease, and in hyperfibrinogenemia. 2. Moderate elevations are common in active inflammatory disease such as rheumatoid arthritis, chronic infections, collagen disease and neoplastic disease*

*3. ESR has little diagnostic value in these disorders but can be useful in monitoring disease activity.*

*4. Useful in the diagnosis and in monitoring polymyalgia rheumatica and temporal arteritis.*

*5. Moderate increase is seen in pregnancy (beginning at the 10th to 12th week) and returns to normal about 1 month postpartum .*

*6. Red cells with an abnormal or irregular shape, such as sickle cells or spherocytes, hinder rouleaux formation and lower the ESR.*



Dr.(Mrs.) Manisha S. Patwardhan  
MD, DPB Reg.No.: 69229

## REPORT

Tel No: 919823027643

PID: 11136697

Age:58.01 Years Sex:FEMALE

## Test Description

## Observed Value

## Biological Reference Interval

Plasma Glucose :

Plasma glucose fasting, by Hexokinase method

111

&lt; 100 mg/dL

100 to 125 mg/dL : Impaired fasting glucose tolerance / Prediabetes

&gt;= 126 mg/dL : Suggestive of diabetes mellitus

(On more than one occasion)

American Diabetes Association

Guidelines 2019

Clinical Chemistry

Urea, serum by GLDH-urease

17

17 to 49 mg/dL

BUN-Blood Urea Nitrogen,serum by calculation

8

8 to 23 mg/dL

Creatinine, serum by Jaffe w/o deproteinization

0.76

0.6 to 1.2 mg/dL

Uric Acid, serum by Uricase method

6.60


Female : 2.60 to 6.00 mg/dL

\* Uric acid is useful for 1. Diagnosis and follow up of renal failure. 2. Monitoring patients receiving cytotoxic drugs and a variety of other disorders, including gout, leukemia, psoriasis, starvation and other wasting conditions

. \* Increased uric acid is seen in following conditions :

1. Increased purine synthesis 2. Inherited metabolic disorders 3. Excess dietary purine intake  
4. Increased nucleic acid turnover 5. Malignancy, cytotoxic drugs 6. Decreased urinary excretion (due to CRF) 7. Increased renal reabsorption .

\* Uric acid is decreased in : 1. Hepatocellular disease with reduced purine synthesis  
2. Defective renal reabsorption 3. Overtreatment of uricemia (allopurinol or cancer therapies like 6-mercaptopurine, etc).



Dr. (Mrs.) Manisha S. Patwardhan  
MD, DPB Reg.No.: 69229

## REPORT

PRAJAKTA G KALE

Reference: Dr.--

SID: 119155495

Collection Date:

04-03-2020 08:54 AM

Sample Date:

04-03-2020 08:54 am

Report Date:

04-03-2020 02:15 PM

Tel No: 919823027643

PID: 11136697

Age: 58.01 Years Sex: FEMALE

### Test Description Clinical Chemistry :

### Observed Value

### Biological Reference Interval

Calcium, serum by OCPC method

**9.00**

8.50 to 10.10 mg/dL

*Method : Colorimetric (o-cresolphthalein substrate) .*

*1. Calcium is useful for diagnosis and monitoring of a wide range of disorders including diseases of bone, kidney, parathyroid gland, or gastrointestinal tract .*

*2. Calcium ions play an important role in blood clotting, bone mineralization, musculature contractility and CNS functioning. .*

*3. Hypocalcemia is due to the absence or impaired function of the parathyroid glands or impaired vitamin-D synthesis. Chronic renal failure is also frequently associated with hypocalcemia due to decreased vitamin-D synthesis as well as hyperphosphatemia and skeletal resistance to the action of parathyroid hormone (PTH).*

*4. Hypercalcemia is mainly due to primary hyperparathyroidism (pHPT), and bone metastasis of carcinoma of the breast, thyroid gland, or lung. Severe hypercalcemia may result in cardiac arrhythmia.*



Dr. (Mrs.) Manisha S. Patwardhan  
MD, DPB Reg.No.: 69229



**REPORT**

Tel No: 919823027643

PID: 11136697

Age:58.01 Years Sex:FEMALE

**Test Description**  
**Clinical Chemistry :****Observed Value****Biological Reference Interval****Hormones**

Free T3, serum by CMIA

**3.18**

1.71 to 3.71 pg/mL

Free T4, serum by CMIA

**1.28**

0.71 to 1.85 ng/dL


TSH(Ultrasensitive), serum by CMIA

**0.04**

For non pregnant female :

0.40 - 4.00  $\mu$ IU/mL

For pregnant female :

1st trimester : 0.1 - 2.5  $\mu$ IU/mL2nd trimester : 0.2 - 3.0  $\mu$ IU/mL3rd trimester : 0.3 - 3.0  $\mu$ IU/mLRef : American Thyroid Association  
guidelines 2017**IMP : Euthyroid , ? Clinical correlation****? On replacement therapy , Otherwise suggested Free T3, Free T4.****Dr.(Mrs.) Manisha S. Patwardhan**  
MD, DPB Reg.No.: 69229**Dr. Awanti Golwilkar**  
MD (Pathology)**Dr. Vinanti Golwilkar**  
MD (Pathology)

**REPORT**

Tel No: 919823027643

PID: 11136697

Age:58.01 Years Sex:FEMALE

Test Description <u>TEST NAME</u>	Observed Value	Biological Reference Interval
--------------------------------------	----------------	-------------------------------

Vitamin B12, serum by CMIA	189.0	187 - 883 pg/mL
----------------------------	-------	-----------------

## Interpretation :

1. Vitamin B12 (cobalamin) is necessary for hematopoiesis and normal neuronal function.


2. Vitamin B12 is decreased in

Decreased Serum B12
Pregnancy Contraceptive hormones Malabsorption Ethanol ingestion Smoking Strict vegan diet Pernicious anemia

3. Serum methylmalonic acid and homocysteine levels are also elevated in vitamin B12 deficiency states.

Active B12 ( Holotranscobalamin) is low in Vitamin B12 deficiency.

4. Please correlate in case of patients taking vitamin B12 supplementation.



**Dr.(Mrs.) Manisha S. Patwardhan**  
MD, DPB Reg.No.: 69229

## REPORT

Tel No: 919823027643

PID: 11136697

Age:58.01 Years Sex:FEMALE

Test Description	Observed Value	Biological Reference Interval
<b>TEST NAME</b>		
25 - OH Vitamin D, serum by CMLA	<b>18.40</b>	Severe deficiency : < 10 ng/mL Mild to moderate deficiency : 10 to 19 ng/mL Optimum levels : 20 to 50 ng/mL Increased risk of hypercalciuria: 51 to 80 ng/mL Toxicity possible : > 80 ng/mL Ref. : Mayo Medical Laboratories These reference ranges represent clinical decision values, based on the 2011 Institute of Medicine report

## Interpretation :

Vitamin D is vital for strong bones. It also has important, emerging roles in immune function and cancer prevention.


Vitamin D compounds in the body are exogenously derived by dietary means; from plants as 25-hydroxyvitamin D2 (ergocalciferol or calciferol) or from animal products as 25-hydroxyvitamin D3 (cholecalciferol or calcidiol).

Vitamin D may also be endogenously derived by conversion of 7-dihydrocholesterol to 25-hydroxyvitamin D3 in the skin upon ultraviolet exposure.

The total 25-hydroxyvitamin D (25-OH-VitD) level (the sum of 25-OH-vitamin D2 and 25-OH-vitamin D3) is the appropriate indicator of vitamin D body stores.

Patients with renal failure can have very high 25-OH-VitD levels without any signs of toxicity, as renal conversion to the active hormone 1,25-OH-VitD is impaired or absent.

Kindly correlate clinically, with supplementation history & repeat with fresh sample if necessary.



Dr.(Mrs.) Manisha S. Patwardhan  
MD, DPB Reg.No.: 69229

## REPORT

Tel No: 919823027643

PID: 11136697

Age:58.01 Years Sex:FEMALE

**Urine Routine Examination**

(Sample : Urine, Automated / Semiautomated)

**Physical****Quantity Examined****Result**

5.0

**Biological Reference Interval**

ml

Method : Visual

**Appearance**

Clear

-

Method : Visual / Automated

**Colour**

Pale yellow

-

Method : Visual / Automated

**Chemical (Dipstick)****pH**

6.5

4.6 - 8.0

Method : Indicator Principle

**Protein**

Absent

Absent

Method : Sulphosalicylic Acid/ pH Indicator

**Glucose**

Absent

Absent

Method : GOD-POD / Benedict's

**Acetone**

Absent

Absent

Method : Sodium Nitroprusside reaction

**Bile Pigments**

Absent

Absent

Method : Diazo Reaction / Fouchet's test

**Urobilinogen**

Not significant

Not Significant

Method : Modified Ehrlich / Watson Schwartz

**Microscopy / Flow cytometry****R.B.Cs**

Occasional

0 - 2 per hpf

**Pus cells**

3-4

0 - 5 per hpf

**Epithelial cells**

4-5

0 - 5 per hpf

**Casts**

Not Detected

-

**Crystals**


Not Detected

-

-

+

End of Report



Dr.(Mrs.) Manisha S. Patwardhan  
MD, DPB Reg.No.: 69229

Page 12 of 12

"Laboratory is accredited as per ISO 15189:2012, Certificate Number MC-3143. Scope available on request / @ www.nabl-india.org"